Registrations:

(1)

Rafael Rosell

ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona)

Registrations: www.doctaforum.com/gecp

Under the Auspices of:

(2)

Thursday, 21

st

_{of November 2013}

08:00 - 10:00 CLINICAL SESSION

Isabel Bover

Fundación Hospital Son Llàtzer, Palma de Mallorca Mª Dolores Isla

Hospital Clínico Univ. Lozano Blesa, Zaragoza 08:00 - 08:15 New developments in SCLC

Edurne Arriola

Hospital del Mar, Barcelona

08:15 - 08:30 Imaging techniques for assessing systemic therapies

Juan Arenas

Hospital General Universitario, Alicante

08:30 - 08:45 New combinations and concurrent CT/RT in Locally Advanced NSCLC

Natividad Martínez

Hospital General Universitario, Elche (Alicante) 08:45 - 09:00 Comprehensive strategies in the treatment

of metastatic NSCLC

Luis Paz-Ares

Hospital Universitario Virgen del Rocío, Sevilla 09:00 - 09:15 Anti-angiogenesis in NSCLC achievements

and new deals (ANGIOMET Trial)

Delvys Rodríguez

Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria

09:15 - 09:30 Special populations in NSCLC: elderly, PS2

María Jové

ICO, Hospital de Bellvitge, L’Hospitalet de Llobregat (Barcelona) 09:30 - 09:45 Immunotherapy in NSCLC: anti-PD1 and anti-PDL1

Santiago Ponce

Hospital Universitario 12 de Octubre, Madrid 09:45 - 10:00 Conclusions

Bartomeu Massutí

Hospital General Universitario, Alicante 10:30 WELCOME

Rafael Rosell

ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona)

Bartomeu Massutí

10:40 - 11:30 SESSION 1: UPDATES ON CLINICAL TRIALS

Rosario García Campelo

Complejo Hospitalario Universitario, A Coruña

Jürgen Wolf

Center for Integrated Oncology, Cologne (Germany)

10:40 - 10:50 BELIEF

Enric Carcereny

ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona) 08:00 - 10:00 CLINICAL SESSION

(3)

Rosario García Campelo

Complejo Hospitalario Universitario, A Coruña

11:00 - 11:10 EUCROSS

Jürgen Wolf

Center for Integrated Oncology, Cologne (Germany)

11:10 - 11:20 NVALT trial in second line squamous cell carcinoma with FGFR1 amplifi cation

Harry J. M. Groen

University Medical Center Groningen, Groningen (The Netherlands)

11:20 – 11:30 Foretinib/erlotinib in EGFR WT NSCLC, second line resistant EGFR mutated patients and ROS1 positive, crizotinib resistant patients

Niki Karachaliou

Hospital Universitario Quirón Dexeus, Barcelona

11:30 - 12:40 SESSION 2: CLINICAL IMPLICATIONS OF RESEARCH IN PATHOLOGY AND LUNG CANCER BIOLOGY

Egbert F. Smit

VU University Medical Center, Amsterdam (The Netherlands)

José L. Ramírez

11:30 - 11:40 Multi-assay genotyping of druggable driver mutations

Katharina König

Uniklinik Köln, Cologne (Germany)

11:40 - 11:50 Relevance of FISH for ALK, ROS1 and RET translocations Hans-Ulrich Schildhaus

University Hospital Göttingen, Göttingen (Germany)

11:50 - 12:00 Concordance of FISH and PCR for EML4-ALK

Cristina Teixidó

Pangaea Biotech, Barcelona

12:00 - 12:10 EML4-ALK and other mutations in blood platelets

Thomas Würdinger

12:10 - 12:20 MLPA assay for multiplexing mutations, copy numbers and fusion transcripts José L. Ramírez

ICO, Hospital Universitario Germans Trias i Pujol,

Badalona (Barcelona)

12:20 - 12:40 Questions and answers. Conclusions Egbert F. Smit

KEYNOTE LECTURE

12:40 - 13:10 Using tumor growth rates to differentiate

cancer therapies

Antonio Tito Fojo

National Cancer Institute, Center for Cancer Research,Bethesda (Maryland, USA)

(4)

Thursday, 21

st

_{of November 2013}

14:10 - 14:40 SESSION 3: BREAKTHROUGHS IN SCLC

AND MESOTHELIOMA

Rolf A. Stahel

University Hospital Zurich, Zurich (Switzerland)

Felipe Cardenal

ICO, Hospital Duran i Reynals, L’Hospitalet de Llobregat (Barcelona)

14:10 - 14:20 HIPPO/YAP pathway for targeted therapy Emanuela Felley-Bosco

14:20 - 14:30 State of the art in mesothelioma management Rolf A. Stahel

14:30 - 14:40 Improving curability in SCLC: A feasible objective?

Pilar Lianes

Hospital de Mataró, Mataró (Barcelona) 14:40 - 15:40 SESSION 4: TARGETED THERAPIES

AND NOVEL AGENTS IN STAGE IV NSCLC

Manuel Dómine

Fundación Jiménez Díaz, Madrid

Enriqueta Felip

Hospital General Vall d’Hebron, Barcelona

14:40 - 14:50 Whole genome sequencing for precise targeted therapy Trever G. Bivona

University of California, San Francisco (California, USA)

14:50 - 15:00 Understanding resistance to EGFR TKIs

in EGFR mutant NSCLC through a serial rebiopsy program

Margarita Majem

Hospital de la Santa Creu i Sant Pau, Barcelona

15:00 - 15:10 c-MET mAb development in lung cancer

Volker Wacheck

Lilly (Austria)

15:10 - 15:20 Targeted therapy in NSCLC driven by HER2 insertions

Solange Peters

Lausanne Cancer Center,

Centre Hospitalier Universitaire Vaudois Lausanne (Switzerland)

15:20 - 15:40 Questions and answers. Conclusions

Enriqueta Felip

15:40 - 16:20 SESSION 5: LOCALLY ADVANCED NSCLC

Wilfried Eberhardt

West German Cancer Center.

University of Essen Medical School, Essen (Germany)

Pilar Garrido

(5)

Wilfried Eberhardt

West German Cancer Center.

University of Essen Medical School Essen (Germany)

15:50 - 16:00 State of the art in treatment

Pilar Garrido

Hospital Universitario Ramón y Cajal, Madrid

16:00 - 16:10 Integration of novel targeted therapies into radiotherapy for lung cancer Mariano Provencio

Hospital Universitario Puerta de Hierro, Majadahonda (Madrid)

Arturo Navarro

ICO, Hospital Duran i Reynals, L’Hospitalet de Llobregat (Barcelona) 16:20 - 16:40 Coffee break

16:40 - 18:00 SESSION 6: ADVANCES IN EARLY STAGE NSCLC

Bartomeu Massutí

Florentino Hernando Trancho

Hospital Clínico Universitario San Carlos, Madrid

16:40 - 16:50 Management of stage I NSCLC patients

Enriqueta Felip

16:50 - 17:00 Adjuvant chemotherapy in stage I high risk patients

José Ramón Jarabo

Hospital Clínico Universitario San Carlos, Madrid

17:00 - 17:10 Customized adjuvant chemotherapy in stage II and III - the SCAT experience Bartomeu Massutí

17:10 - 17:20 State of the art of adjuvant chemotherapy in Stage II and III NSCLC patients

Ángel Artal

Hospital Universitario Miguel Servet, Zaragoza

17:20 - 17:30 State of the art in surgery for early NSCLC. Does the number of resected lymph nodes matter?

Laura Romero

17:30 - 17:40 CTCs in monitoring resected NSCLC Andreas-Claudius Hoffmann

West German Cancer Center. Uniklinikum Essen,

Essen (Germany)

17:40 - 18:00 Questions and answers. Conclusions Javier de Castro

(6)

Friday, 22

nd

_{of November 2013}

08:00 - 08:30 SLCG PLENARY SESSION 08:30 - 08:45 PLENARY LECTURE

08:30 - 08:45 Moving forward to synthetic lethal approaches for improving survival in NSCLC

Rafael Rosell

ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona) 08:45 -09:55 SESSION 7: MOLECULAR SCREENING

FOR SYNTHETIC LETHALITY APPROACHES

Niki Karachaliou

Trever G. Bivona

08:45 - 08:55 KRAS mutations Rolf A. Stahel

08:55- 09:05 BRAF mutations José M. Sánchez

Hospital Universitario de La Princesa, Madrid

09:05 - 09:15 Predicting resistance by selection of signaling pathways

Niki Karachaliou

09:15 - 09:25 Combination targeted therapy in EGFR

mutant patients

Trever G. Bivona

09:25 - 09:35 Combination targeted therapy in EML4-ALK translocated patients Santiago Viteri

09:35 - 09:55 Questions & answers. Conclusions

Santiago Ponce

Hospital Universitario 12 de Octubre, Madrid 09:55 - 10:15 Coffee break

KEYNOTE LECTURE

10:15 - 10:45 Improving the activity of epigenetic therapies Susan E. Bates

National Cancer Institute, Center for Cancer Research, Bethesda (Maryland, USA)

10:45 - 10:55 SESSION 8: STATE OF THE ART IN TRANSLATIONAL RESEARCH

Miguel A. Molina

Mariano Provencio

(7)

Miguel A. Molina

10:55 - 11:05 Transcriptional regulators for refi nement of lung cancer subtypes Cristina Teixidó

Pangaea Biotech, Barcelona

11:05 - 11:15 From the bench to the bed: the unmet need for progress Egbert F. Smit

11:15 - 11:25 Lessons from the BREC study: opportunities remain for customizing chemotherapy

Manuel Cobo

Hospital Universitario Carlos Haya, Málaga

11:25 – 11:35 Elderly patients: how old is too old for translational research? 70, 90? Alain Vergnenègre

Cluzeau University Hospital, Limoges (France)

Noemí Reguart

Hospital Clínic Universitari, Barcelona

11:55– 12:25 SESSION 9: CRUCIAL ROLE OF THE THORACIC SURGEON

Laureano Molins

Hospital Clínic, Barcelona

Nicolás Moreno

Hospital Universitario Virgen del Rocío, Sevilla

11:55 - 12:05 Surgical implications of the new pathological classifi cation of adenocarcinoma

Íñigo Royo

Hospital Universitario Miguel Servet, Zaragoza

12:05 - 12:15 VATS resections in NSCLC: Oncological Results Pedro López de Castro

Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona)

12:30 - 12:25 Surgical management of metachronic and synchronic second primary lung tumors Íker López Sanz

Hospital General Vall d’Hebrón, Barcelona 12:25 - 12:40 PLENARY LECTURE

12:25 - 12:40 DNA stability and cisplatin resistance in NSCLC

Ken O’Byrne

Queensland University of Technology, Brisbane (Queensland, Australia)

12:40 - 12:50 Closing remarks

Rafael Rosell

Bartomeu Massutí

(8)

VENUE

Auditori AXA Avda. Diagonal, 547 08029 Barcelona (Spain)

LANGUAGE

Lectures will be delivered in English or Spanish.

CREDITS

Accredited by the European Society for Medical Oncology Educational Committee Working Group for its medical oncology certifi cation approval program with 10 ESMO-MORA category 1 points.

ORGANIZING & SCIENTIFIC COMMITTEE

Carlos Camps, Hospital General Universitario, Valencia

Enric Carcereny, ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona)

Felipe Cardenal, ICO, Hospital Duran i Reynals, L’Hospitalet de Llobregat (Barcelona)

Javier de Castro, Hospital Universitario La Paz, Madrid

Manuel Cobo, Hospital Universitario Carlos Haya, Málaga

Manuel Dómine, Fundación Jiménez Díaz, Madrid

Rosario García Campelo, Complejo Hospitalario Universitario, A Coruña

Florentino Hernando-Trancho, Hospital Clínico Universitario San Carlos, Madrid

Dolores Isla, Hospital Clínico Universitario Lozano Blesa, Zaragoza

Eloísa Jantús, Hospital General Universitario, Valencia

Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona

Bartomeu Massutí, Hospital General Universitario, Alicante

Teresa Morán, ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona)

Mariano Provencio, Hospital Universitario Puerta de Hierro, Majadahonda (Madrid)

Noemí Reguart, Hospital Clínic Universitari, Barcelona

Rafael Rosell, ICO,Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona)

José Javier Sánchez, Universidad Autónoma de Madrid

José Miguel Sánchez, Hospital Universitario de la Princesa, Madrid

Miquel Taron, Pangaea Biotech, Barcelona MAJOR SPONSORS

OTHER SPONSORS

CONFERENCE SECRETARIAT

Monasterios de Suso y Yuso 34, 4-14-2 · 28049 Madrid Tel.: +34 91 372 02 03 - Email: [email protected] www.doctaforum.com/gecp